Evidence Based Medicine on FHIR Implementation Guide
2.0.0-ballot - ballot
Evidence Based Medicine on FHIR Implementation Guide
2.0.0-ballot - ballot
Evidence Based Medicine on FHIR Implementation Guide, published by HL7 International / Clinical Decision Support. This guide is not an authorized publication; it is the continuous build for version 2.0.0-ballot built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/ebm/ and changes regularly. See the Directory of published versions
| Active as of 2024-11-21 |
Generated Narrative: Citation 179616
version: 8; Last updated: 2024-07-18 17:58:30+0000
Profile: JournalArticleCitation
url: Citation 26244877 Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer.
identifier: FEvIR Object Identifier/179616, https://pubmed.ncbi.nlm.nih.gov/26244877, Uniform Resource Identifier (URI)/urn:oid:2.16.840.1.113883.4.642.40.44.15.17
version: 2.0.0-ballot
title: 26244877 Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer.
status: Active
date: 2024-11-21 14:09:14+0000
publisher: HL7 International / Clinical Decision Support
contact: HL7 International / Clinical Decision Support: http://www.hl7.org/Special/committees/dss
description:
This Citation Resource is referenced in an example for the EBMonFHIR Implementation Guide.
| Code | Value[x] |
| Citation Classification Type fevir-platform-use: FEvIR Platform Use | Medline Base |
jurisdiction: World
copyright:
https://creativecommons.org/licenses/by-nc-sa/4.0/
approvalDate: 2015-08-25
lastReviewDate: 2024-06-10
author: Computable Publishing®: MEDLINE-to-FEvIR Converter:
classification
type: Citation Source
classifier: MEDLINE
classification
type: MEDLINE Citation Owner
classifier: National Library of Medicine, Index Section
currentState: Medline Citation Status of Medline, PubMed PublicationStatus of ppublish
statusDate
activity: PubMed Pubstatus of Entrez
period: ?? --> 2015-08-06 06:00:00+0000
statusDate
activity: PubMed Pubstatus of Pubmed
period: ?? --> 2015-08-06 06:00:00+0000
statusDate
activity: PubMed Pubstatus of Medline
period: ?? --> 2015-08-26 06:00:00+0000
statusDate
activity: PubMed Pubstatus of PMC release
period: ?? --> 2016-02-20
citedArtifact
identifier:
https://pubmed.ncbi.nlm.nih.gov/26244877, mid/NIHMS719565,https://www.ncbi.nlm.nih.gov/pmc//PMC4562797,https://doi.org/10.1056/NEJMoa1503747relatedIdentifier:
https://clinicaltrials.gov/NCT00309985Titles
Type Language Text Primary title English Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer.
Abstracts
Text BACKGROUND: Androgen-deprivation therapy (ADT) has been the backbone of treatment for metastatic prostate cancer since the 1940s. We assessed whether concomitant treatment with ADT plus docetaxel would result in longer overall survival than that with ADT alone. METHODS: We assigned men with metastatic, hormone-sensitive prostate cancer to receive either ADT plus docetaxel (at a dose of 75 mg per square meter of body-surface area every 3 weeks for six cycles) or ADT alone. The primary objective was to test the hypothesis that the median overall survival would be 33.3% longer among patients receiving docetaxel added to ADT early during therapy than among patients receiving ADT alone. RESULTS: A total of 790 patients (median age, 63 years) underwent randomization. After a median follow-up of 28.9 months, the median overall survival was 13.6 months longer with ADT plus docetaxel (combination therapy) than with ADT alone (57.6 months vs. 44.0 months; hazard ratio for death in the combination group, 0.61; 95% confidence interval [CI], 0.47 to 0.80; P<0.001). The median time to biochemical, symptomatic, or radiographic progression was 20.2 months in the combination group, as compared with 11.7 months in the ADT-alone group (hazard ratio, 0.61; 95% CI, 0.51 to 0.72; P<0.001). The rate of a prostate-specific antigen level of less than 0.2 ng per milliliter at 12 months was 27.7% in the combination group versus 16.8% in the ADT-alone group (P<0.001). In the combination group, the rate of grade 3 or 4 febrile neutropenia was 6.2%, the rate of grade 3 or 4 infection with neutropenia was 2.3%, and the rate of grade 3 sensory neuropathy and of grade 3 motor neuropathy was 0.5%. CONCLUSIONS: Six cycles of docetaxel at the beginning of ADT for metastatic prostate cancer resulted in significantly longer overall survival than that with ADT alone. (Funded by the National Cancer Institute and others; ClinicalTrials.gov number, NCT00309985.).
relatesTo
type: cites
classifier: Journal Article
citation:
Huggins C, Hodges CV. Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res. 1941;1:293–7.
Documents
Url https://pubmed.ncbi.nlm.nih.gov/0/ resourceReference: Identifier:
https://pubmed.ncbi.nlm.nih.gov/0relatesTo
type: cites
classifier: Journal Article
citation:
Prostate Cancer Trialists’ Collaborative Group. Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Lancet. 2000;355:1491–8.
Documents
Url https://pubmed.ncbi.nlm.nih.gov/10801170/ resourceReference: Identifier:
https://pubmed.ncbi.nlm.nih.gov/10801170relatesTo
type: cites
classifier: Journal Article
citation:
Samson DJ, Seidenfeld J, Schmitt B, et al. Systematic review and meta-analysis of monotherapy compared with combined androgen blockade for patients with advanced prostate carcinoma. Cancer. 2002;95:361–76.
Documents
Url https://pubmed.ncbi.nlm.nih.gov/12124837/ resourceReference: Identifier:
https://pubmed.ncbi.nlm.nih.gov/12124837relatesTo
type: cites
classifier: Journal Article
citation:
Hussain M, Tangen CM, Berry DL, et al. Intermittent versus continuous androgen deprivation in prostate cancer. N Engl J Med. 2013;368:1314–25.
Documents
Url https://pubmed.ncbi.nlm.nih.gov/23550669/ resourceReference: Identifier:
https://pubmed.ncbi.nlm.nih.gov/23550669relatesTo
type: cites
classifier: Journal Article
citation:
Tangen CM, Hussain MH, Higano CS, et al. Improved overall survival trends of men with newly diagnosed M1 prostate cancer: a SWOG phase III trial experience (S8494, S8894 and S9346) J Urol. 2012;188:1164–9.
Documents
Url https://pubmed.ncbi.nlm.nih.gov/22921015/ resourceReference: Identifier:
https://pubmed.ncbi.nlm.nih.gov/22921015relatesTo
type: cites
classifier: Journal Article
citation:
Wu JN, Fish KM, Evans CP, Devere White RW, Dall’Era MA. No improvement noted in overall or cause-specific survival for men presenting with metastatic prostate cancer over a 20-year period. Cancer. 2014;120:818–23.
Documents
Url https://pubmed.ncbi.nlm.nih.gov/24258693/ resourceReference: Identifier:
https://pubmed.ncbi.nlm.nih.gov/24258693relatesTo
type: cites
classifier: Journal Article
citation:
Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351:1513–20.
Documents
Url https://pubmed.ncbi.nlm.nih.gov/15470214/ resourceReference: Identifier:
https://pubmed.ncbi.nlm.nih.gov/15470214relatesTo
type: cites
classifier: Journal Article
citation:
Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351:1502–12.
Documents
Url https://pubmed.ncbi.nlm.nih.gov/15470213/ resourceReference: Identifier:
https://pubmed.ncbi.nlm.nih.gov/15470213relatesTo
type: cites
classifier: Journal Article
citation:
Millikan RE, Wen S, Pagliaro LC, et al. Phase III trial of androgen ablation with or without three cycles of systemic chemotherapy for advanced prostate cancer. J Clin Oncol. 2008;26:5936–42.
Documents
Url https://pubmed.ncbi.nlm.nih.gov/19029421/ resourceReference: Identifier:
https://pubmed.ncbi.nlm.nih.gov/19029421relatesTo
type: cites
classifier: Journal Article
citation:
Gravis G, Fizazi K, Joly F, et al. Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial. Lancet Oncol. 2013;14:149–58.
Documents
Url https://pubmed.ncbi.nlm.nih.gov/23306100/ resourceReference: Identifier:
https://pubmed.ncbi.nlm.nih.gov/23306100relatesTo
type: cites
classifier: Journal Article
citation:
Crawford ED, Eisenberger MA, McLeod DG, et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med. 1989;321:419–24.
Documents
Url https://pubmed.ncbi.nlm.nih.gov/2503724/ resourceReference: Identifier:
https://pubmed.ncbi.nlm.nih.gov/2503724relatesTo
type: cites
classifier: Journal Article
citation:
Eisenberger MA, Blumenstein BA, Crawford ED, et al. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med. 1998;339:1036–42.
Documents
Url https://pubmed.ncbi.nlm.nih.gov/9761805/ resourceReference: Identifier:
https://pubmed.ncbi.nlm.nih.gov/9761805relatesTo
type: cites
classifier: Journal Article
citation:
Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst. 2000;92:205–16.
Documents
Url https://pubmed.ncbi.nlm.nih.gov/10655437/ resourceReference: Identifier:
https://pubmed.ncbi.nlm.nih.gov/10655437relatesTo
type: cites
citation:
Jennison CTB. Statistical approaches to interim monitoring of medical trials: a review and commentary. Stat Sci. 1990;5:299–317.
relatesTo
type: cites
citation:
Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457–81.
relatesTo
type: cites
citation:
Cox DR. Regression models and life-tables. J R Stat Soc B. 1972;34:187–220.
relatesTo
type: cites
classifier: Journal Article
citation:
Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966;50:163–70.
Documents
Url https://pubmed.ncbi.nlm.nih.gov/5910392/ resourceReference: Identifier:
https://pubmed.ncbi.nlm.nih.gov/5910392relatesTo
type: cites
citation:
Cox D. Analysis of binary data. London: Methuen and Co; 1970.
relatesTo
type: cites
classifier: Journal Article
citation:
de Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011;364:1995–2005.
Documents
Url https://pubmed.ncbi.nlm.nih.gov/21612468/ resourceReference: Identifier:
https://pubmed.ncbi.nlm.nih.gov/21612468relatesTo
type: cites
classifier: Journal Article
citation:
Ryan CJ, Smith MR, de Bono JS, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med. 2013;368:138–48.
Documents
Url https://pubmed.ncbi.nlm.nih.gov/23228172/ resourceReference: Identifier:
https://pubmed.ncbi.nlm.nih.gov/23228172relatesTo
type: cites
classifier: Journal Article
citation:
Beer TM, strong AJ, Rathkopf DE, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014;371:424–33.
Documents
Url https://pubmed.ncbi.nlm.nih.gov/24881730/ resourceReference: Identifier:
https://pubmed.ncbi.nlm.nih.gov/24881730relatesTo
type: cites
classifier: Journal Article
citation:
Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367:1187–97.
Documents
Url https://pubmed.ncbi.nlm.nih.gov/22894553/ resourceReference: Identifier:
https://pubmed.ncbi.nlm.nih.gov/22894553relatesTo
type: cites
classifier: Journal Article
citation:
Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363:411–22.
Documents
Url https://pubmed.ncbi.nlm.nih.gov/20818862/ resourceReference: Identifier:
https://pubmed.ncbi.nlm.nih.gov/20818862relatesTo
type: cites
classifier: Journal Article
citation:
de Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010;376:1147–54.
Documents
Url https://pubmed.ncbi.nlm.nih.gov/20888992/ resourceReference: Identifier:
https://pubmed.ncbi.nlm.nih.gov/20888992relatesTo
type: cites
classifier: Journal Article
citation:
Parker C, Nilsson S, Heinrich D, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013;369:213–23.
Documents
Url https://pubmed.ncbi.nlm.nih.gov/23863050/ resourceReference: Identifier:
https://pubmed.ncbi.nlm.nih.gov/23863050relatesTo
type: cites
classifier: Journal Article
citation:
James ND, Spears MR, Clarke NW, et al. Survival with newly diagnosed metastatic prostate cancer in the “docetaxel era”: data from 917 patients in the control of the STAMPEDE trial (MRC PR08, CRUK/06/019) Eur Urol. 2015;67:1028–38.
Documents
Url https://pubmed.ncbi.nlm.nih.gov/25301760/ resourceReference: Identifier:
https://pubmed.ncbi.nlm.nih.gov/25301760relatesTo
type: comment-in
classifier: Comment
citation:
BMJ. 2015 Aug 05;351:h4253. doi: 10.1136/bmj.h4253
Documents
Url https://pubmed.ncbi.nlm.nih.gov/26251343/ resourceReference: Identifier:
https://pubmed.ncbi.nlm.nih.gov/26251343relatesTo
type: comment-in
classifier: Comment
citation:
Nat Rev Clin Oncol. 2015 Oct;12(10):563. doi: 10.1038/nrclinonc.2015.145
Documents
Url https://pubmed.ncbi.nlm.nih.gov/26305034/ resourceReference: Identifier:
https://pubmed.ncbi.nlm.nih.gov/26305034relatesTo
type: comment-in
classifier: Comment
citation:
Nat Rev Urol. 2015 Dec;12(12):656-8. doi: 10.1038/nrurol.2015.255
Documents
Url https://pubmed.ncbi.nlm.nih.gov/26526753/ resourceReference: Identifier:
https://pubmed.ncbi.nlm.nih.gov/26526753relatesTo
type: comment-in
classifier: Comment
citation:
Nat Rev Clin Oncol. 2015 Dec;12(12):687-8. doi: 10.1038/nrclinonc.2015.192
Documents
Url https://pubmed.ncbi.nlm.nih.gov/26552950/ resourceReference: Identifier:
https://pubmed.ncbi.nlm.nih.gov/26552950relatesTo
type: comment-in
classifier: Comment
citation:
BMC Med. 2015 Dec 22;13:304. doi: 10.1186/s12916-015-0543-9
Documents
Url https://pubmed.ncbi.nlm.nih.gov/26695172/ resourceReference: Identifier:
https://pubmed.ncbi.nlm.nih.gov/26695172relatesTo
type: comment-in
classifier: Comment
citation:
J Urol. 2016 Jan;195(1):94. doi: 10.1016/j.juro.2015.10.055
Documents
Url https://pubmed.ncbi.nlm.nih.gov/26699961/ resourceReference: Identifier:
https://pubmed.ncbi.nlm.nih.gov/26699961relatesTo
type: comment-in
classifier: Comment
citation:
N Engl J Med. 2016 Jan 21;374(3):287. doi: 10.1056/NEJMc1511800
Documents
Url https://pubmed.ncbi.nlm.nih.gov/26789883/ resourceReference: Identifier:
https://pubmed.ncbi.nlm.nih.gov/26789883relatesTo
type: comment-in
classifier: Comment
citation:
N Engl J Med. 2016 Jan 21;374(3):286. doi: 10.1056/NEJMc1511800
Documents
Url https://pubmed.ncbi.nlm.nih.gov/26789884/ resourceReference: Identifier:
https://pubmed.ncbi.nlm.nih.gov/26789884relatesTo
type: comment-in
classifier: Comment
citation:
Eur Urol. 2016 Mar;69(3):540. doi: 10.1016/j.eururo.2015.12.027
Documents
Url https://pubmed.ncbi.nlm.nih.gov/26867727/ resourceReference: Identifier:
https://pubmed.ncbi.nlm.nih.gov/26867727relatesTo
type: comment-in
classifier: Comment
citation:
Eur Urol. 2016 Apr;69(4):755-6. doi: 10.1016/j.eururo.2016.01.020
Documents
Url https://pubmed.ncbi.nlm.nih.gov/26972499/ resourceReference: Identifier:
https://pubmed.ncbi.nlm.nih.gov/26972499relatesTo
type: comment-in
classifier: Comment
citation:
Eur Urol. 2016 Jan;69(1):178. doi: 10.1016/j.eururo.2015.10.037
Documents
Url https://pubmed.ncbi.nlm.nih.gov/27099882/ resourceReference: Identifier:
https://pubmed.ncbi.nlm.nih.gov/27099882relatesTo
type: comment-in
classifier: Comment
citation:
Urol Oncol. 2017 Mar;35(3):123. doi: 10.1016/j.urolonc.2016.12.021
Documents
Url https://pubmed.ncbi.nlm.nih.gov/28159490/ resourceReference: Identifier:
https://pubmed.ncbi.nlm.nih.gov/28159490publicationForm
publishedIn
type: Periodical
identifier: Electronic ISSN Type/1533-4406, ISOAbbreviation/N Engl J Med, ISSN Linking/0028-4793, Medline Title Abbreviation/N Engl J Med, NLM Unique ID/0255562
title: The New England journal of medicine
publisherLocation: United States
citedMedium: Internet
volume: 373
issue: 8
articleDate: 2015-08-20
publicationDateText: 2015-Aug-20
language: English
pageString: 737-46
publicationForm
citedMedium: Internet without issue
articleDate: 2015-08-05
webLocation
classifier: Abstract
webLocation
classifier: DOI Based
classification
type: Publishing Model
classifier: Print Electronic
classification
type: Chemical
classifier: Androgen Antagonists, Antineoplastic Agents, Taxoids, Docetaxel, Prostate-Specific Antigen
classification
type: MeSH heading
artifactAssessment: ArtifactAssessment: artifact[x] = this resource
classification
type: Publication type
classifier: Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't
classification
type: Knowledge Artifact Type
classifier: Journal Article
artifactAssessment: Classifier added by Computable Publishing LLC
classification
type: Citation subset
classifier: IM
contributorship
complete: true
entry
contributor: Sweeney CJ
forenameInitials: CJ
affiliation: From the Department of Medicine (C.J.S.) and the Department of Biostatistics and Computational Biology (Y.-H.C.), Dana-Farber Cancer Institute, Boston; Harvard Medical School, Boston (C.J.S.); Johns Hopkins University, Baltimore (M.C., M.E.); University of Wisconsin Carbone Cancer Center (G.L., D.F.J.) and School of Medicine and Public Health (D.F.J.), Madison; Fox Chase Cancer Center, Temple University Health System, Philadelphia (Y.-N.W.); Indiana University Melvin and Bren Simon Cancer Center, Indianapolis (N.H.); Mayo Clinic, Rochester, MN (M.K.); University Hospitals Case Medical Center, Seidman Cancer Center (M.M.C.), and Cleveland Clinic Taussig Cancer Institute (J.A.G.) - both in Cleveland; University of Virginia Cancer Center, Charlottesville (R.D.); Comprehensive Cancer Centers of Nevada, Las Vegas (N.J.V.); Siteman Cancer Center, Washington University School of Medicine, St. Louis (J.P.); NorthShore University HealthSystem, Evanston, IL (D.S.); University of Michigan Comprehensive Cancer Center, Ann Arbor (M.H.); and Rutgers Cancer Institute of New Jersey, New Brunswick (R.S.D.).
entry
contributor: Chen YH
forenameInitials: YH
entry
contributor: Carducci M
forenameInitials: M
entry
contributor: Liu G
forenameInitials: G
entry
contributor: Jarrard DF
forenameInitials: DF
entry
contributor: Eisenberger M
forenameInitials: M
entry
contributor: Wong YN
forenameInitials: YN
entry
contributor: Hahn N
forenameInitials: N
entry
contributor: Kohli M
forenameInitials: M
entry
contributor: Cooney MM
forenameInitials: MM
entry
contributor: Dreicer R
forenameInitials: R
entry
contributor: Vogelzang NJ
forenameInitials: NJ
entry
contributor: Picus J
forenameInitials: J
entry
contributor: Shevrin D
forenameInitials: D
entry
contributor: Hussain M
forenameInitials: M
entry
contributor: Garcia JA
forenameInitials: JA
entry
contributor: DiPaola RS
forenameInitials: RS
Generated Narrative: Practitioner #contributor0
name: Christopher J Sweeney
Generated Narrative: Practitioner #contributor1
name: Yu-Hui Chen
Generated Narrative: Practitioner #contributor2
name: Michael Carducci
Generated Narrative: Practitioner #contributor3
name: Glenn Liu
Generated Narrative: Practitioner #contributor4
name: David F Jarrard
Generated Narrative: Practitioner #contributor5
name: Mario Eisenberger
Generated Narrative: Practitioner #contributor6
name: Yu-Ning Wong
Generated Narrative: Practitioner #contributor7
name: Noah Hahn
Generated Narrative: Practitioner #contributor8
name: Manish Kohli
Generated Narrative: Practitioner #contributor9
name: Matthew M Cooney
Generated Narrative: Practitioner #contributor10
name: Robert Dreicer
Generated Narrative: Practitioner #contributor11
name: Nicholas J Vogelzang
Generated Narrative: Practitioner #contributor12
name: Joel Picus
Generated Narrative: Practitioner #contributor13
name: Daniel Shevrin
Generated Narrative: Practitioner #contributor14
name: Maha Hussain
Generated Narrative: Practitioner #contributor15
name: Jorge A Garcia
Generated Narrative: Practitioner #contributor16
name: Robert S DiPaola
Generated Narrative: ArtifactAssessment #meshHeading0
artifact: Citation 26244877 Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer.
content
informationType: Classifier
type: components (if present) include qualifier codings
classifier: Adult
freeToShare: true
Components
Type Classifier qualifier is not a major topic content
informationType: Classifier
type: components (if present) include qualifier codings
classifier: Aged
freeToShare: true
Components
Type Classifier qualifier is not a major topic content
informationType: Classifier
type: components (if present) include qualifier codings
classifier: Aged, 80 and over
freeToShare: true
Components
Type Classifier qualifier is not a major topic content
informationType: Classifier
type: components (if present) include qualifier codings
classifier: Androgen Antagonists
freeToShare: true
component
type: qualifier
classifier: is not a major topic
component
type: qualifier
classifier: adverse effects
Components
Type Classifier is Major topic No component
type: qualifier
classifier: therapeutic use
Components
Type Classifier is Major topic Yes content
informationType: Classifier
type: components (if present) include qualifier codings
classifier: Antineoplastic Agents
freeToShare: true
component
type: qualifier
classifier: is not a major topic
component
type: qualifier
classifier: adverse effects
Components
Type Classifier is Major topic No component
type: qualifier
classifier: therapeutic use
Components
Type Classifier is Major topic Yes content
informationType: Classifier
type: components (if present) include qualifier codings
classifier: Docetaxel
freeToShare: true
Components
Type Classifier qualifier is not a major topic content
informationType: Classifier
type: components (if present) include qualifier codings
classifier: Drug Therapy, Combination
freeToShare: true
Components
Type Classifier qualifier is not a major topic content
informationType: Classifier
type: components (if present) include qualifier codings
classifier: Follow-Up Studies
freeToShare: true
Components
Type Classifier qualifier is not a major topic content
informationType: Classifier
type: components (if present) include qualifier codings
classifier: Humans
freeToShare: true
Components
Type Classifier qualifier is not a major topic content
informationType: Classifier
type: components (if present) include qualifier codings
classifier: Kaplan-Meier Estimate
freeToShare: true
Components
Type Classifier qualifier is not a major topic content
informationType: Classifier
type: components (if present) include qualifier codings
classifier: Male
freeToShare: true
Components
Type Classifier qualifier is not a major topic content
informationType: Classifier
type: components (if present) include qualifier codings
classifier: Middle Aged
freeToShare: true
Components
Type Classifier qualifier is not a major topic content
informationType: Classifier
type: components (if present) include qualifier codings
classifier: Neutropenia
freeToShare: true
component
type: qualifier
classifier: is not a major topic
component
type: qualifier
classifier: chemically induced
Components
Type Classifier is Major topic No component
type: qualifier
classifier: epidemiology
Components
Type Classifier is Major topic No content
informationType: Classifier
type: components (if present) include qualifier codings
classifier: Prostate-Specific Antigen
freeToShare: true
component
type: qualifier
classifier: is not a major topic
component
type: qualifier
classifier: blood
Components
Type Classifier is Major topic No content
informationType: Classifier
type: components (if present) include qualifier codings
classifier: Prostatic Neoplasms
freeToShare: true
component
type: qualifier
classifier: is not a major topic
component
type: qualifier
classifier: drug therapy
Components
Type Classifier is Major topic Yes component
type: qualifier
classifier: mortality
Components
Type Classifier is Major topic No component
type: qualifier
classifier: pathology
Components
Type Classifier is Major topic No content
informationType: Classifier
type: components (if present) include qualifier codings
classifier: Taxoids
freeToShare: true
component
type: qualifier
classifier: is not a major topic
component
type: qualifier
classifier: adverse effects
Components
Type Classifier is Major topic No component
type: qualifier
classifier: therapeutic use
Components
Type Classifier is Major topic Yes
IG © 2024+ HL7 International / Clinical Decision Support. Package hl7.fhir.uv.ebm#2.0.0-ballot based on FHIR 6.0.0-ballot2. Generated 2024-11-21
Links: Table of Contents |
QA Report
| Version History |
|
Propose a change